Drug discovery and human African trypanosomiasis: A disease less neglected?

Lori Ferrins, Raphael Steve Rahmani, Jonathan Bayldon Baell

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Human African trypanosomiasis (HAT) has been neglected for a long time. The most recent drug to treat this disease, eflornithine, was approved by the US FDA in 2000. Current treatments exhibit numerous problematic side effects and are often ineffective against the debilitating CNS resident stage of the disease. Fortunately, several partnerships and initiatives have been formed over the last 20 years in an effort to eradicate HAT, along with a number of other neglected diseases. This has led to an increasing number of foundations and research institutions that are currently working on the development of new drugs for HAT and tools with which to diagnose and treat patients. New biochemical pathways as therapeutic targets are emerging, accompanied by increasing numbers of new antitrypanosomal compound classes. The future looks promising that this collaborative approach will facilitate eagerly awaited breakthroughs in the treatment of HAT.
Original languageEnglish
Pages (from-to)1801 - 1841
Number of pages41
JournalFuture Medicinal Chemistry
Volume5
Issue number15
DOIs
Publication statusPublished - 2013

Cite this

Ferrins, Lori ; Rahmani, Raphael Steve ; Baell, Jonathan Bayldon. / Drug discovery and human African trypanosomiasis: A disease less neglected?. In: Future Medicinal Chemistry. 2013 ; Vol. 5, No. 15. pp. 1801 - 1841.
@article{fa9d8468e2ca4e8290fc75b12e2f97af,
title = "Drug discovery and human African trypanosomiasis: A disease less neglected?",
abstract = "Human African trypanosomiasis (HAT) has been neglected for a long time. The most recent drug to treat this disease, eflornithine, was approved by the US FDA in 2000. Current treatments exhibit numerous problematic side effects and are often ineffective against the debilitating CNS resident stage of the disease. Fortunately, several partnerships and initiatives have been formed over the last 20 years in an effort to eradicate HAT, along with a number of other neglected diseases. This has led to an increasing number of foundations and research institutions that are currently working on the development of new drugs for HAT and tools with which to diagnose and treat patients. New biochemical pathways as therapeutic targets are emerging, accompanied by increasing numbers of new antitrypanosomal compound classes. The future looks promising that this collaborative approach will facilitate eagerly awaited breakthroughs in the treatment of HAT.",
author = "Lori Ferrins and Rahmani, {Raphael Steve} and Baell, {Jonathan Bayldon}",
year = "2013",
doi = "10.4155/fmc.13.162",
language = "English",
volume = "5",
pages = "1801 -- 1841",
journal = "Future Medicinal Chemistry",
issn = "1756-8919",
publisher = "Future Science",
number = "15",

}

Drug discovery and human African trypanosomiasis: A disease less neglected? / Ferrins, Lori; Rahmani, Raphael Steve; Baell, Jonathan Bayldon.

In: Future Medicinal Chemistry, Vol. 5, No. 15, 2013, p. 1801 - 1841.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Drug discovery and human African trypanosomiasis: A disease less neglected?

AU - Ferrins, Lori

AU - Rahmani, Raphael Steve

AU - Baell, Jonathan Bayldon

PY - 2013

Y1 - 2013

N2 - Human African trypanosomiasis (HAT) has been neglected for a long time. The most recent drug to treat this disease, eflornithine, was approved by the US FDA in 2000. Current treatments exhibit numerous problematic side effects and are often ineffective against the debilitating CNS resident stage of the disease. Fortunately, several partnerships and initiatives have been formed over the last 20 years in an effort to eradicate HAT, along with a number of other neglected diseases. This has led to an increasing number of foundations and research institutions that are currently working on the development of new drugs for HAT and tools with which to diagnose and treat patients. New biochemical pathways as therapeutic targets are emerging, accompanied by increasing numbers of new antitrypanosomal compound classes. The future looks promising that this collaborative approach will facilitate eagerly awaited breakthroughs in the treatment of HAT.

AB - Human African trypanosomiasis (HAT) has been neglected for a long time. The most recent drug to treat this disease, eflornithine, was approved by the US FDA in 2000. Current treatments exhibit numerous problematic side effects and are often ineffective against the debilitating CNS resident stage of the disease. Fortunately, several partnerships and initiatives have been formed over the last 20 years in an effort to eradicate HAT, along with a number of other neglected diseases. This has led to an increasing number of foundations and research institutions that are currently working on the development of new drugs for HAT and tools with which to diagnose and treat patients. New biochemical pathways as therapeutic targets are emerging, accompanied by increasing numbers of new antitrypanosomal compound classes. The future looks promising that this collaborative approach will facilitate eagerly awaited breakthroughs in the treatment of HAT.

UR - http://www.future-science.com/doi/abs/10.4155/fmc.13.162

U2 - 10.4155/fmc.13.162

DO - 10.4155/fmc.13.162

M3 - Article

VL - 5

SP - 1801

EP - 1841

JO - Future Medicinal Chemistry

JF - Future Medicinal Chemistry

SN - 1756-8919

IS - 15

ER -